CHMP Positive On Safinamide, First New Parkinson’s Therapy In 10 Years
This article was originally published in The Pink Sheet Daily
Executive Summary
Newron expects partner Zambon to start marketing safinamide in the first half of 2015 in Europe, and to resubmit it soon for U.S. approval. Other positive CHMP opinions this month include Orexigen’s obesity therapy Mysimba and Durata’s antibiotic Xydalba.